These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17201088)

  • 21. A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study).
    Boyd MA; Truman M; Hales G; Anderson J; Dwyer DE; Carr A
    Antivir Ther; 2008; 13(3):449-53. PubMed ID: 18572758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials.
    Palladino C; Briz V; González-Tomé MI; León Leal JA; Navarro ML; de José MI; Ramos JT; Muñoz-Fernández MA
    AIDS Res Hum Retroviruses; 2010 Mar; 26(3):301-5. PubMed ID: 20334565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure.
    Svicher V; Aquaro S; D'Arrigo R; Artese A; Dimonte S; Alcaro S; Santoro MM; Di Perri G; Caputo SL; Bellagamba R; Zaccarelli M; Visco-Comandini U; Antinori A; Narciso P; Ceccherini-Silberstein F; Perno CF
    J Infect Dis; 2008 May; 197(10):1408-18. PubMed ID: 18419549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
    De Castro N; Braun J; Charreau I; Pialoux G; Cotte L; Katlama C; Raffi F; Weiss L; Meynard JL; Yazdanpanah Y; Delaugerre C; Madelaine-Chambrin I; Aboulker JP; Molina JM;
    Clin Infect Dis; 2009 Oct; 49(8):1259-67. PubMed ID: 19757993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Strategies for combating resistances in HIV therapy--an exemplifying case].
    Stoehr A
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
    [No Abstract]   [Full Text] [Related]  

  • 26. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
    Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
    Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients.
    Viard JP; Fagard C; Chaix ML; Rouzioux C; Bouteloup V; Bentata M; de Verdière NC; Pahlavan G; Weiss L; Lévy Y; Chêne G;
    AIDS; 2009 Jul; 23(11):1383-8. PubMed ID: 19461505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life and tolerability after administration of enfuvirtide with a thin-walled needle: QUALITE Study.
    Shalit P; True A; Thommes JA;
    HIV Clin Trials; 2007; 8(1):24-35. PubMed ID: 17434846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector).
    Harris M; Joy R; Larsen G; Valyi M; Walker E; Frick LW; Palmatier RM; Wring SA; Montaner JS
    AIDS; 2006 Mar; 20(5):719-23. PubMed ID: 16514302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
    Cervia JS; Smith MA
    Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.
    Wiznia A; Church J; Emmanuel P; Eppes S; Rowell L; Evans C; Bertasso A;
    Pediatr Infect Dis J; 2007 Sep; 26(9):799-805. PubMed ID: 17721374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
    Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
    J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS).
    Lalezari JP; Saag M; Walworth C; Larson P
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):805-13. PubMed ID: 18507525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
    J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
    Goebel FD
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
    [No Abstract]   [Full Text] [Related]  

  • 37. Lack of benefit of 3-month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: the INNOVE study.
    Morand-Joubert L; Ghosn J; Delaugerre C; Giffo B; Solas C; Samri A; Pinta A; Triglia A; Raffi F;
    J Med Virol; 2012 Nov; 84(11):1710-8. PubMed ID: 22997073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enfuvirtide and cutaneous injection-site reactions.
    Mirza RA; Turiansky GW
    J Drugs Dermatol; 2012 Oct; 11(10):e35-8. PubMed ID: 23134996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration.
    Loutfy MR; Harris M; Raboud JM; Antoniou T; Kovacs C; Shen S; Dufresne S; Smaill F; Rouleau D; Rachlis A; Gough K; Lalonde R; Tsoukas C; Trottier B; Walmsley SL; Montaner JS
    HIV Med; 2007 Oct; 8(7):427-32. PubMed ID: 17760734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enfuvirtide: patient acceptance and strategies for managing injection-site reactions.
    Rice C; Wilantewicz H
    AIDS Read; 2006 Sep; 16(9):470-4, 490-1. PubMed ID: 17024766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.